Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | +67.53% |
Business Summary
TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Managers
Managers | Title | Age | Since |
---|---|---|---|
Caroline Courme
IRO | Public Communications Contact | - | 16-02-29 |
Corporate Officer/Principal | - | - | |
Matthieu Allez
PRN | Corporate Officer/Principal | - | - |
Bernard Malissen
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | 61 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Duncan Mckay
CHM | Chairman | - | 19-02-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 23,195,394 | 1,045,009 ( 4.505 %) | 0 | 4.505 % |
Company contact information
Sangamo Therapeutics France SAS
Les Cardoulines HT1 Allée de la Nertière
06560, Valbonne
+33 4 97 21 83 00
http://txcell.com/Sector
1st Jan change | Capi. | |
---|---|---|
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- TXCL Stock
- Company TxCell